The purpose of this study is to determine whether individuals with schizophrenia who will take a high dose of the B-vitamins folate, B12 and pyridoxine, may experience improvement in their symptoms.
Individuals with schizophrenia often experience disturbing residual symptoms, even with the best available current treatments. Homocysteine, normally found in the body, can interfere with NMDA-glutamate receptor function, and this might be responsible for some of the symptoms of schizophrenia. This double-blind protocol will have study participants who suffer from schizophrenia take either a high-dose combination of folate, B12 and pyridoxine (a combination that can lower homocysteine in the body) or placebo for three months. Clinical measures (e.g., PANSS, CGI) will be taken to determine whether those taking the vitamin combination experience clinical benefit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
50
placebo capsule
The Nathan Kline Institute for Psychiatric Research
Orangeburg, New York, United States
blood homocysteine levels
Time frame: 12 weeks after baseline
CGI (Clinical Global Improvement)
Time frame: 12 weeks after baseline
CDSS (Calgary Depression Scale for Schizophrenia)
Time frame: 12 weeks after baseline
WAIS-II Memory Scale (Immediate and Delayed)
Time frame: 12 weeks after baseline
WAIS Digit Symbol-Coding
Time frame: 12 weeks after baseline
Wisconsin Card Sorting Test
Time frame: 12 weeks after baseline
WAIS-II Letter-Number Sequencing Subtest
Time frame: 12 weeks after baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.